FXR
Farnesoid X Receptor (FXR) is a nuclear receptor that plays a key role in the regulation of bile acid homeostasis, lipid metabolism, and glucose regulation. FXR is a potential therapeutic target for treating liver diseases, metabolic disorders, and cardiovascular diseases. FXR inhibitors can modulate these pathways, offering insights into disease mechanisms and therapeutic strategies. At CymitQuimica, we provide a range of FXR inhibitors to support your research in hepatology, metabolism, and drug development.
Products of "FXR"
Sort by
BAR502
CAS:BAR502 is a dual GPBAR1 and FXR agonist (IC50s: 0.4 μM and 2 μM).Formula:C25H44O3Purity:99.95%Color and Shape:SolidMolecular weight:392.62Chenodeoxycholic acid
CAS:Chenodeoxycholic acid (CDCA), a bile acid, usually conjugated with either glycine or taurine, acts as a detergent to solubilize fats for intestinal absorption.Formula:C24H40O4Purity:99.70% - 99.72%Color and Shape:White - Almost White Solid PowderMolecular weight:392.57FXR agonist 5
CAS:FXR agonist 5 is an FXR agonist used in the study of liver diseases or diseases mediated by metabolic inflammation.Formula:C40H53N5O5Purity:99.74%Color and Shape:SolidMolecular weight:683.88Nidufexor
CAS:Nidufexor is an agonist for the farnesoid X receptor (FXR).Formula:C27H22ClN3O4Purity:98.67%Color and Shape:SolidMolecular weight:487.93GW 4064
CAS:GW 4064 is an effective farnesoid X receptor (FXR) agonist (EC50 =65 nM).Formula:C28H22Cl3NO4Purity:97.47% - 99.94%Color and Shape:SolidMolecular weight:542.84Ref: TM-T2233
5mg50.00€10mg84.00€25mg139.00€50mg235.00€100mg424.00€200mg640.00€500mg1,008.00€1mL*10mM (DMSO)63.00€LH10
LH10 is an FXR agonist based on fexaramine, with an EC50 of 0.14 μM. It offers hepatoprotective effects, mitigating conditions such as cholestasis induced by alpha naphthylisothiocyanate (ANIT), acute liver injury caused by APAP, and non-alcoholic steatohepatitis (NASH).Formula:C34H33N3O2Color and Shape:SolidMolecular weight:515.64Gly-β-MCA
CAS:Gly-β-MCA is an orally bioactive, entero inhibitor of the farnesoid X receptor (FXR), a bile acid, used in the study of obesity and diabetes.Formula:C26H43NO6Purity:≥98.0%Color and Shape:SolidMolecular weight:465.62LY367385
CAS:LY367385 is a highly effective and selective mGluR1a antagonist.Formula:C10H11NO4Purity:98%Color and Shape:SolidMolecular weight:209.2ZLY28
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1.Formula:C29H23Cl2NO4Purity:98%Color and Shape:SolidMolecular weight:520.4FXR/CES2 modulator 1
CAS:Compound LE-77, known as FXR/CES2 modulator 1, functions as a dual regulator that activates FXR and inhibits CES2. It effectively mitigates the intestinal toxicity of irinotecan.Formula:C27H21Cl2NO5Color and Shape:SolidMolecular weight:510.36NR1H4 Protein, Human, Recombinant (His)
NR1H4 Protein, Human, Recombinant (His) is expressed in E.Color and Shape:Lyophilized PowderMolecular weight:27.83 kDa (predicted)Glyco-Obeticholic acid
CAS:Glyco-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an agonist of the farnesoid X receptor (FXR).Formula:C28H47NO5Purity:99.77% - 99.95%Color and Shape:SolidMolecular weight:477.68Fexaramine
CAS:Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity compared to natural compounds.Formula:C32H36N2O3Purity:98.87% - 99.61%Color and Shape:SolidMolecular weight:496.64Osocimab
CAS:Osocimab (BAY 1213790) is a strong FXIa inhibitor, Ki 2.4 nM, EC50 0.2 nM, and reduces thrombosis in research.Purity:> 95% - > 95%Color and Shape:LiquidMolecular weight:144.46 kDaFXR agonist 12
CAS:FXR agonist12 (Compound C7) is an orally active FXR agonist. It downregulates bile acid synthesis-related genes and upregulates bile acid transport-related genes in HepG2 cells. FXR agonist12 alleviates ANIT-induced cholestasis and reduces liver damage and fibrosis in a mouse model of NASH.Formula:C26H44O3Color and Shape:SolidMolecular weight:404.626GSK2324
CAS:GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis.Formula:C29H22Cl2N2O4Purity:100% - 98.50%Color and Shape:SolidMolecular weight:533.4NDB
CAS:NDB is a hFXRα antagonist that inhibits GW4064-stimulated FXR/RXR interactions in primary mouse hepatocytes.NDB is used in the study of diabetes.Formula:C26H28Cl2N2O2Purity:98.94%Color and Shape:SolidMolecular weight:471.42Tauro-β-muricholic acid sodium
CAS:Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM).Formula:C26H44NNaO7SPurity:98%Color and Shape:SolidMolecular weight:537.69Tauro-β-muricholic acid
CAS:Tauro-β-muricholic acid (TβMCA), a trihydroxylated bile acid, acts as a competitive and reversible FXR antagonist (IC 50 = 40 μM) and exhibits antiapoptoticFormula:C26H45NO7SPurity:98%Color and Shape:SolidMolecular weight:515.7Chenodeoxycholic Acid sodium salt
CAS:Chenodeoxycholic Acid sodium salt (CDCA sodium salt) is a bile acid in humans that activates the nuclear receptor FXR, rescues axonal degeneration of induced pluripotent stem cell-derived neurons in patients with spastic paraplegia type 5 and cerebral xanthomatosis, and can be used to study pancreatic necrosis.Formula:C24H39NaO4Purity:99.68% - 99.72%Color and Shape:SolidMolecular weight:414.55
